Tagged Articles

type 2 80 articles

Study shows daily insulin injections do not raise risk for heart attack, stroke, cancer

The safety of diabetes medications has been a concern since the Food and Drug Administration (FDA) issued warnings about cancer and heart attacks associated with the type 2 diabetes drugs Actos and Avandia. For decades, people have wondered if the use of another diabetes medication – insulin – made diabetics more susceptible to cardiovascular disease and cancer. But, a new study offers some peace of mind, indicating long-term, daily injections of insulin do not appear to increase the risk for heart attacks, strokes, or cancer in people with type 2 diabetes or pre-diabetes. The new international study, led by Canadian researchers, ... Read More

New diabetes drugs have to provide more proof they are safe

These days, drugs to treat diabetes have one of the highest safety standards to clear before they are granted approval by the Food and Drug Administration (FDA). Placebo-controlled studies are no longer enough to sway agency decision makers. Drug companies must prove their new diabetes treatments won’t cause more problems than the condition they are treating. Which is why excitement over promising data from phase II studies on LY2605541, a joint effort by Eli Lilly and Boehringer Ingelheim, is contained. The drug showed better or equal glycemic control for patients with type 1 or type 2 diabetes than other similar ... Read More

Aggressive approach needed to prevent diabetes in pre-diabetics

An earlier and more aggressive approach is needed in people at risk for developing type 2 diabetes in order to reduce the escalating number of people diagnosed with the disease each year, according to a study published in the Lancet. Type 2 diabetes is on the rise worldwide and unhealthy diets and sedentary lifestyles are to blame. People in the early stages of diabetes, known as pre-diabetes, who ignore important warning signs, such as elevated blood sugar, will most likely go on to develop the condition. Once someone develops type 2 diabetes, it is almost impossible to fully recover. However, ... Read More

Experimental type 2 diabetes drug shows promise in African American adults

An experimental drug for type 2 diabetes is showing promising results in African American adults in a late-stage clinical trial. The once-daily tablet, marketed by Boehringer Ingelheim as Tradjenta, helped reduce blood sugar levels in patients whose blood sugar had not been previously adequately controlled. It is in a class of medications known as DPP-4 inhibitors, which work different from other diabetes medications by inhibiting glucagon and blood sugar levels. African Americans are at a 77 percent greater risk of developing type 2 diabetes than Caucasians. Nearly 20 percent – or about 4.9 million – African American adults are living ... Read More

Actos carries even greater risk for bladder cancer, heart attack, death

The type 2 diabetes drug Actos (pioglitazone) carries an even greater risk for bladder cancer and heart problems than previously noted during a Food and Drug Administration (FDA) review, according to a new study published in the British Medical Journal. Actos is in a class of type 2 diabetes medications known as thiazolidinediones, or TZDs. Another member in this class is Avandia (rosiglitazone). The safety of both drugs has come under scrutiny in recent years. In 2010, the FDA severely restricted the use of Avandia after the drug was linked to fatal heart attacks. Actos was considered a safer choice ... Read More

Actos, Avandia more likely to cause bladder cancer than other diabetes drugs

Patients taking a class of medications used to treat type 2 diabetes are far more likely to develop bladder cancer than patients on other types of diabetes drugs, according to a new British study. The study pitted glitazones against sulfonylurea agents, both medications used to treat type 2 diabetes. Glitazones, or thiazolidinediones, work by controlling blood sugar by improving insulin sensitivity. Glitazones on the market today include the popular diabetes treatments pioglitazone (Actos) and rosiglitazone (Avandia). Sulfonylurea agents are in a class known as anti-diabetic agents, and work by helping the pancreas produce more insulin. Sulfonylurea agents include the drug ... Read More

Study finds Avandia-plus-metformin is best for young type 2 diabetics

A drug made of metformin and Avandia is better at controlling blood sugar levels in children and adolescents with type 2 diabetes than metformin alone, but the serious risks associated with Avandia raise concerns about the new drug combo. Avandia is a type 2 diabetes medication that was severely restricted by the Food and Drug Administration (FDA) in 2010 after the drug was linked to fatal heart attacks. Actos, another type 2 diabetes medication, is in the same class of medications and was recently linked to bladder cancer. The new study, called the Treatment Options for Type 2 Diabetes in Adolescents and ... Read More

Study links sleep apnea to type 2 diabetes

People who suffer from sleep apnea are more likely to suffer from type 2 diabetes  than people who have a more restful night’s sleep, according to a new study presented at the American Thoracic Society (ATS) 2012 International Conference. Researchers also concluded that low oxygen levels in the blood during sleep hours, a symptom of sleep apnea, is linked to levels of glycosylated hemoglobin (HbA1c), a targeted indicator for diabetes. Previous studies have linked sleep apnea and sleep disturbances to a higher risk for type 2 diabetes. In 2007, a study from Yale showed the risk of diabetes among people ... Read More

Experimental type 2 diabetes drug meets FDA’s cardiovascular goals

An experimental type 2 diabetes drug met Food and Drug Administration (FDA) goals for blood pressure and heart rate effects during a 16-week study. The results of the study showed the effects of Ely Lilly’s drug dulaglutide on systolic blood pressure was comparable to placebo, and the 1.5 milligram dose significantly reduced blood pressure. The study included 755 patients with type 2 diabetes on one or more oral diabetes medications. About two-thirds of the patients had a pre-existing diagnosis of hypertension. Dulaglutide, a once-weekly treatment, also appeared to significantly reduce HbA1c, or average blood glucose levels over a three-month period ... Read More

Actos for depression puts more at risk for bladder cancer

A new study shows that the type 2 diabetes drug Actos (pioglitazone) has been shown to be an effective treatment for major depressive disorder (MDD), but does this benefit outweigh its risk for cancer? Actos is in a class of medications known as thiazolidinediones (TZDs), or glitazones, medications used to treat type 2 diabetes. Other drugs in this class include Avandia (rosiglitazone) and Rezulin (troglitazone). TZDs have shown to help relieve depression symptoms in animal studies and in uncontrolled studies evaluating with people who have MDD and metabolic syndrome, including type 2 diabetes. While these drugs are insulin sensitizers, they also have ... Read More